Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 30, 2013SpringerPlusOpen Access

Bioequivalance and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBabu Rao ChanduGokula Krishna College of PharmacyKKKanchanamala KanalaNHNagiat T. HwisaUniversity of Illinois Urbana-Champaign

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chandu et al. (2013) studied this question.

synapsesocial.com/papers/6a74b9d9fd85dc918409122chttps://doi.org/10.1186/2193-1801-2-194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects2010 · 59 citations
  2. 2PK/PD and Safety of a Single Dose of TMX‐67 (Febuxostat) in Subjects with Mild and Moderate Renal Impairment2004 · 57 citations